VERTEX PHARMACEUTICALSInsider Trading & SEC Form 4 Analysis
Institutional analysis of internal capital flows based on SEC Form 4 filings.
-$75.4M
Buys minus sales2026.07.02
Latest Form 417
Reporting entitiesNo buyer detected
No open-market buysSachdev Amit
$9.2MAutomated_Intelligence_Report :: VRTX
Algorithmic analysis of recent insider trading activity for VRTX reveals a bearish posture among the C-suite and board members. Based on the latest SEC Form 4 filings, we have tracked capital events executed by 17 distinct corporate insiders. The aggregate nominal exposure during this reporting cycle reached $104.87M.
Market dynamics show a negative net capital flow of $75.36M when isolating open-market purchases versus open-market sales. The trading volume is heavily weighted towards open-market executions, providing a clearer signal of insider conviction regarding current valuation levels compared to option-based equity grants.
From a microstructural perspective, the most significant liquidity event was a divestment by Sachdev Amit (Officer/Other), which accounts for a major share of the recent outflow. Continuous monitoring of these Tier-1 actors is essential, as their liquidity decisions often precede material corporate events or reflect an informed, asymmetric perspective on the future performance of VRTX.
$104.87M
USD NOMINAL VALUE17
UNIQUE C-SUITE ENTITIES2026.07.02
ISO_8601 FORMATAutomated_Queries :: Frequently Asked Questions
>How many corporate insiders are active in VRTX?
Our dataset currently tracks 17 distinct insiders with reported transactions for VRTX in the active reporting window.
>Is insider buying outweighing selling at VRTX?
Open-market selling volume ($75.36M) currently exceeds buying volume ($0.00M), indicating net liquidation by insiders.
>Who is currently buying VRTX stock?
Our algorithmic tracking of SEC Form 4 filings indicates no significant open-market buying activity by major executives for VRTX in the recent reporting period.